NewslettersMammary Cell News PRMT5 Is an Actionable Therapeutic Target in CDK4/6 Inhibitor-Resistant ER+/RB-Deficient Breast Cancer By Emily Salmini - March 13, 2024 0 Through a genome-wide CRISPR screen, investigators identified protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability in ER+/RB1-knockout breast cancer cells. [Nature Communications] Full Article